|| List of recent Peptide-related patents
|Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Polynucleotides and polypeptides in plants|
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
|Compositions and methods for altering alpha- and beta-tocotrienol content|
Preparation and use of isolated nucleic acids useful in altering the oil phenotype in plants. Isolated nucleic acids and their encoded polypeptides that alter alpha- and beta-tocotrienol content in seeds and oil obtained from the seeds.
|Polynucleotides and polypeptides that confer increased yield, size or biomass|
The present description relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant, including the traits of increased yield, size or biomass.. .
|Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics|
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a trkb receptor molecule..
|Modified polynucleotides for treating carboxypeptidase n, polypeptide 1 protein deficiency|
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmrna molecules.. .
|Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements|
This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements..
|Cell-permeable peptide inhibitors of the jnk signal transduction pathway|
The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-jun amino terminal kinase. Additionally, the present invention provides jnk inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with jnk signaling..
|Treatment of cardiac arrhythmias|
Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (glp-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment..
|Wnt compositions and methods of use thereof|
Wnt compositions and methods for their use are provided. Compositions of the invention comprise fragments of wnt polypeptides having a desired biological activity, which fragments are referred to herein as “mini-wnts”.
|Peptide bfp4 for promoting osteogenesis or vascularization and use thereof|
Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced.
|Compositions and methods to immunize against hepatitis c virus|
Compositions comprising viral antigens and antigenic peptides corresponding to or derived from hepatitis c virus (hcv) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (dcs) are described herein. Included herein are immunostimulatory compositions (hcv vaccines, hcv antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of hcv antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis c in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis c..
|Immunotherapeutic methods using epitopes of wt-1 and gata-1|
A peptide comprising the amino acid sequence rmfpnapyl or a portion or variant thereof provided that the peptide is not intact human wt-1 polypeptide or a peptide comprising the amino acid sequence cmtwnqmnl or a portion or variant thereof provided that the peptide is not intact human wt-1 polypeptide or a peptide comprising the amino acid sequence hlmpfpgpll or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines..
A method for releasing the content of the periplasmic space of bacterial cells is provided, which comprises incubating the bacterial cells in a solution containing styrene maleic acid copolymer (sma). Also provided is a method of preparing a substantially pure sample of recombinant polypeptide.
|Multiplex mrm assay for evaluation of cancer|
The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (er), progesterone receptor (pr), and/or antigen ki67 (ki67) proteins that are particularly advantageous for quantifying the er, pr, and/or ki67 proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring/multiple reaction monitoring (srm/mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
|Isotopic recoding for targeted tandem mass spectrometry|
Aspects of the present disclosure include methods for detecting a low abundance protein and methods for identifying a site of n-glycosylation on a protein. In practicing methods according to certain embodiments, a eukaryotic cell is contacted with an isotopic labeling composition and isotopically labeled n-glycosylated peptides obtained from the eukaryotic cell are assessed by liquid chromatography-tandem mass spectrometry.
|Method for determining glucagon-like peptide-1, and kit for use in said method|
Provided is a method of measuring the presence and/or the amount of glucagon-like peptide-1 (glp-1) in a sample, which method is characterized by comprising the step of treating the sample in advance with an acidic solution, and a kit of measuring the presence and/or an amount of glp-1 in a sample, the kit containing (a) the acidic solution, (b) an antibody specific to glp-1, and (c) an instruction manual.. .
|Glucanases, nucleic acids encoding them and methods for making and using them|
The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-d-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-d-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-d-glucans or xyloglucans and other plant material containing cellulosic parts.
|Influenza b viruses having alterations in the hemaglutinin polypeptide|
The present invention encompasses methods of producing influenza b viruses in cell culture. The influenza b viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza b virus infection..
|Therapeutic agent for emphysema and copd|
The invention described herein relates to methods of treating emphysema and copd with a ghk tripeptide. The invention further relates to methods of determining the state of the lungs using biomarkers described herein..
|Vaccines for protection from and treatment of alzheimer's disease|
Disclosed herein are dna-based vaccines against amyloid β peptide for use in treating and alleviating alzheimer's disease and related conditions. A dna construct comprising dna encoding one or more amyloid β peptides, such as amino acids 1-11 of aβ, and dna encoding a hepatitis b antigens, is administered with an adjuvant or by electroporation.
|Tmem22 peptides and vaccines including the same|
Isolated peptides composed of the amino acid sequence of seq id no: 33 or fragments thereof that bind to hla antigens and have cytotoxic t lymphocyte (ctl) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic t cell inducibility.
|C1orf59 peptides and vaccines including the same|
The present invention provides isolated peptides having the amino acid sequence of seq id no: 43 or immunologically active fragments thereof, which bind to hla antigen and have cytotoxic t lymphocyte (ctl) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic t cell inducibility.
|Therapeutic compounds for immunomodulation|
The present invention provides immunosuppressive compounds capable of inhibiting the programmed cell death 1 (pd1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by pd-1, pd-l1, or pd-l2 and therapies using them, immunopotentiative substrates included as the active ingredient.
|Aquaporin-4 peptides, compositions and methods of use|
The present disclosure provides human aquaporin 4 (aqp4) peptides and peptides having homology to human aquaporin 4 (aqp4) peptides. Also provided herein are methods for using human aqp4 peptides and peptides homologous to human aqp4 peptides for diagnosing and/or treating neuromyelitis optica..
|Method of treating cancer with an hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same|
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a wt1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of ala, ile, leu, val, phe, tyr, ser and asp and an amino acid residue at position 9 in the amino acid sequence is arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.. .
|Novel polypeptides and use thereof|
The present invention provides a polypeptides capable of modulating tissue transglutarmnase-induced cell behaviour wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a lissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of seq id no: 1, the invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same..
|Stabilizing polypeptides which have been exposed to urea|
Methods for stabilizing polypeptides, such as anti-her2 antibodies, which have been exposed to urea.. .
|Modulators of the nlrp3 inflammasome il-1beta pathway for the prevention and treatment of acne|
The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of il-1β, il-1 receptor type 1, nlrp3, asc, caspase-1 and cathepsin b with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of il-1β, il-1 receptor type 1, il-1 receptor type 2, nlrp3, asc and caspase-1. Similarly, an interfering rna or an antisense modulator of gene expression of il-1β, i l-1β receptor type 1, nlrp3, asc, caspase-1 and cathepsin b are provided for the prevention or treatment of acne..
|Methods of treating complications and disorders associated with g-csf administration|
The present embodiments relate to novel uses of mpo inhibitors and inhibitors of mpo and e-selectin binding. In some embodiments, methods are provided for treating g-csf-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits e-selectin receptor/ligand interaction or inhibits mpo activity.
|Process for the production of fine chemicals|
The present invention relates to a process for the production of the fine chemical in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof, preferably in plastids. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use..
|Compositions comprising agents that inhibit neuropilin and tolloid like 2|
We disclose agents that inhibit the expression of neto-2 which has elevated expression in cancer stem cells; the use of neto-2 as a diagnostic or prognostic marker of tumour initiation; the use neto-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind neto-2 and vaccines comprising neto-2 polypeptides.. .
|Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1|
The present invention features methods for treating or ameliorating tissue damage using intravenous administration of compositions that include stromal cell derived factor-1 (sdf-1) peptides or mutant sdf-1 peptides that have been mutated to make them resistant to protease digestion, but which retain chemoattractant activity. Systemic delivery, and specifically intravenous (“iv”) delivery, of sdf-1 and protease resistant sdf-1 mutants is very effective for the treatment of tissue damage..
|Compositions for regulating iron homeostasis and methods of using same|
The present disclosure relates to hemojuvelin-igg fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.. .
The present inventors produced a heterodimerized polypeptide having an fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an fc region with improved fc region function compared to that of a homodimer in which the fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.. .
|Structural mutations in titin cause dilated cardiomyopathy|
Provided herein are diagnostic markers and methods for identifying a subject having an increased susceptibility for developing or having dilated cardiomyopathy. The method comprises determining if the subject has a mutation in the ttn nucleic as acid or titin polypeptide.
|Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof|
Provided are soluble neutral active hyaluronidase glycoproteins (shasegp's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
|Compositions and methods for detection and treatment of cancer|
Novel antibodies for the detection and/or treatment of a cancer (e.g., a pancreatic cancer or an ovarian cancer) are provided. In certain embodiments the antibodies bind a region of the muc4 protein that does not comprise the central tandem repeat (tr) domain of muc4.
|Method for isolating cell-type specific mrnas|
The invention provides methods for isolating cell-type specific mrnas by selectively isolating ribosomes or proteins that bind mrna in a cell type specific manner, and, thereby, the mrna hound to the ribosomes or proteins that bind mrna. Ribosomes, which are riboprotein complexes, bind mrna that is being actively translated in cells.
|Axmi221z, axmi222z, axmi223z, axmi224z and axmi225z delta-endotoxin genes and methods for their use|
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
|Plants having altered agronomic characteristics under nitrogen limiting conditions and related constructs and methods involving genes encoding lnt6 polypeptides and homologs thereof|
Isolated polynucleotides and polypeptides and recombinant dna constructs particularly useful for altering agronomic characteristics of plants under nitrogen limiting conditions, compositions (such as plants or seeds) comprising these recombinant dna constructs, and methods utilizing these recombinant dna constructs. The recombinant dna construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes an lnt6 polypeptide or homolog thereof..
|Organelle targeting nanocarriers|
Provided are organelle targeting nanocarriers, including peptides, which act to deliver biological molecules such as nucleic acids to non-nuclear organelles such as mitochondria and chloroplasts. Also provided are methods for genetic transformation of non-nuclear organelles using such nanocarriers..
|Plant transcriptional regulators|
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having improved tolerance to drought, shade, and low nitrogen conditions, as compared to wild-type or reference plants.. .
|B7-related nucleic acids and polypeptides useful for immunomodulation|
The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3.
|Modified chimeric polypeptides with improved pharmacokinetic properties|
The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component..
|Synthetic peptides and peptide mimetics|
The present invention provides parotid secretory protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening gl13 mimetics.. .
|Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use|
The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight.
|Sequence-specific inhibition of small rna function|
The present invention relates to the discovery of a method for inhibiting rna silencing in a target sequence-specific manner. Rna silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide.
|Cyclic lactadherin peptide mimetics and their uses|
Provided herein is a new class of cyclic lactadherin peptides (clac) that mimic the natural phosphatidylserine (ps)-binding activity of the parent lactadherin protein. These clacs are useful as small molecule indicators of early stage of apoptosis and of treatment efficacy evaluation..
|Use of endostatin peptides for the treatment of fibrosis|
C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed.
|Vault agents for treating chronic kidney disease|
The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a rgd-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease.. .
|Interfering rna delivery system and uses thereof|
The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering rna molecule. The system can be used for delivering interfering rna molecules into a cell in vivo or in vitro.
|Prominin-1 peptide fragments and uses thereof|
Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase vegf binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration..
|Modified relaxin polypeptides and their uses|
Modified relaxin polypeptides and their uses thereof are provided. .
|Isolated nucleic acid molecules encoding variant activin receptor polypeptides|
The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
|Methods for treatment of nephrotic syndrome and related conditions|
The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein.
|Compositions and methods for treatment of metabolic disorders and diseases|
The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21), and variants or fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.. .
|Hemipteran-and coleopteran active toxin proteins from bacillus thuringiensis|
A novel bacillus thuringiensis crystal protein exhibiting insect inhibitory activity is disclosed. Growth of lygus insects is significantly inhibited by providing the novel crystal protein in lygus insect diet.
|Influenza inhibiting compositions and methods|
The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (fir) of a wild-type influenza hemagglutinin 2 protein or a variant thereof.
|Novel depsipeptide and uses thereof|
The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.. .
|Fusion peptide designed to reduce plaque bacteria and yeast in the oral cavity|
The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to lactoferrin and pak fusion peptides (pak-lf), along with therapeutic, diagnostic and research uses for these polypeptides.
|Peptide-based peroxidase inhibitors and methods of using same|
The present invention provides peptide-based peroxidase inhibitors having the formula aa1-aa2-aa3, wherein aa1 is a positively charged, negatively charged or neutral amino acid, aa2 is a redox active amino acid, and aa3 is an amino acid possessing a reducing potential such that aa3 is capable of undergoing a redox reaction with a radical of amino acid aa2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury.
|Biomarkers for diagnosing alzheimer's disease|
A method for assessing the state of alzheimer's disease in patients is disclosed. A method for monitoring the progression of alzheimer's disease in patients is also disclosed.